Context Therapeutics Appoints New Director

TL;DR

Context Therapeutics adds Dr. Jonathan T. Raper to its board.

AI Summary

Context Therapeutics Inc. announced on September 4, 2024, a change in its board of directors. Dr. Jonathan T. Raper has been appointed as a new director, effective immediately. This appointment is part of the company's ongoing efforts to strengthen its leadership and strategic direction.

Why It Matters

The addition of a new director can signal strategic shifts or a focus on specific areas of expertise, potentially impacting the company's future growth and development.

Risk Assessment

Risk Level: low — The filing reports a routine board appointment, which typically carries low immediate risk.

Key Players & Entities

• Context Therapeutics Inc. (company) — Registrant
• Jonathan T. Raper (person) — Newly appointed director
• September 4, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — mon Stock CNTX The Nasdaq Stock Market $0.001 par value per share Indicate by check
• $960 million — ntares Pharma (acquired by Halozyme for $960 million), Acceleron Pharma (acquired by Merck f
• $11.5 billion — Acceleron Pharma (acquired by Merck for $11.5 billion), Mariana Oncology (acquired by Novarti
• $1 billion — iana Oncology (acquired by Novartis for $1 billion upfront), and Sucampo Pharmaceuticals (
• $1.2 billion — ceuticals (acquired by Mallinckrodt for $1.2 billion). Dr. Smith currently serves on the boa
• $680 million — was acquired by Merck in March 2024 for $680 million. From March 2018 to October 2022, Dr. W
• $614 million — hich was acquired by Seagen in 2018 for $614 million. Dr. Walker began his career as a pract
• $40,000 — to time, which currently consists of a $40,000 annual cash retainer, payable quarterly

Filing Documents

• cntx-20240904.htm (8-K) — 31KB
• a20240904-boardappointment.htm (EX-99.1) — 12KB
• image_0a.jpg (GRAPHIC) — 193KB
• 0001842952-24-000070.txt ( ) — 448KB
• cntx-20240904.xsd (EX-101.SCH) — 2KB
• cntx-20240904_lab.xml (EX-101.LAB) — 24KB
• cntx-20240904_pre.xml (EX-101.PRE) — 14KB
• cntx-20240904_htm.xml (XML) — 3KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On September 4, 2024, the Company issued a press release announcing the appointments of Dr. Smith and Dr. Walker to the Board. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01, and Exhibit 99.1 attached hereto, are being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

01. Exhibits

Item 9.01. Exhibits. ( d) Exhibits Exhibit No. Description 99.1 Press Release issued by Context Therapeutics Inc., dated September 4 , 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 4, 2024 Context Therapeutics Inc. By: /s/ Martin A. Lehr Name: Martin A. Lehr Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR